Mariam Gachechiladze

Mariam Gachechiladze

Auto-generated profile, based on publicly available information

Mariam Gachechiladze

Department of Clinical and Molecular Pathology, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czechia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2014 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
GKGvantsa Kharaishvili
Gvantsa Kharaishvili
DSDana Simkova
Dana Simkova
KBkaterina bouchalova
katerina bouchalova
MGMariam Gachechiladze
Mariam Gachechiladze
NNNato Narsia
Nato Narsia
JBJan Bouchal
Jan Bouchal
Tumors are not merely masses of neoplastic cells but complex tissues composed of cellular and noncellular elements. This review provides recent data on the main components of a dynamic system, such as carcinoma associated fibroblasts that change the extracellular matrix (ECM) topology, induce stemness and promote metastasis-initiating cells. Altered production and characteristics of collagen, hyaluronan and other ECM proteins induce increased matrix stiffness. Stiffness along with tumor growth-induced solid stress and increased interstitial fluid pressure contribute to tumor progression and therapy resistance. Second, the role of immune cells, cytokines and chemokines is outlined. We discuss other noncellular characteristics of the tumor microenvironment such as hypoxia and extracellular pH in relation to neoangiogenesis. Overall, full understanding of the events driving the interactions between tumor cells and their environment is of crucial importance in overcoming treatment resistance and improving patient outcome.

19 May 2017 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
MGMariam Gachechiladze
Mariam Gachechiladze
JSJozef Skarda
Jozef Skarda
ASAlex Soltermann
Alex Soltermann
Markus JoergerMarkus Joerger
Markus Joerger

Verified
Journal Article
Open access
PDF file
AMAlena Mičková
Alena Mičková
GKGvantsa Kharaishvili
Gvantsa Kharaishvili
DKDaniela Kurfurstova
Daniela Kurfurstova
MGMariam Gachechiladze
Mariam Gachechiladze
MKMilan Kral
Milan Kral
JBJan Bouchal
Jan Bouchal
Prostate cancer (PCa) is the second leading cause of cancer-related deaths in men in Western countries, and there is still an urgent need for a better understanding of PCa progression to inspire new treatment strategies. Skp2 is a substrate-recruiting component of the E3 ubiquitin ligase complex, whose activity is regulated through neddylation. Slug is a transcriptional repressor involved in the epithelial-to-mesenchymal transition, which may contribute to therapy resistance. Although Skp2 has previously been associated with a mesenchymal phenotype and prostate cancer progression, the relationship with Slug deserves further elucidation. We have previously shown that a high Gleason score (≥8) is associated with higher Skp2 and lower E-cadherin expression. In this study, significantly increased expression of Skp2, AR, and Slug, along with E-cadherin downregulation, was observed in primary prostate cancer in patients who already had lymph node metastases. Skp2 was slightly correlated with Slug and AR in the whole cohort (Rs 0.32 and 0.37, respectively), which was enhanced for both proteins in patients with high Gleason scores (Rs 0.56 and 0.53, respectively) and, in the case of Slug, also in patients with metastasis to lymph nodes (Rs 0.56). Coexpression of Skp2 and Slug was confirmed in prostate cancer tissues by multiplex immunohistochemistry and confocal microscopy. The same relationship between these two proteins was observed in three sets of prostate epithelial cell lines (PC3, DU145, and E2) and their mesenchymal counterparts. Chemical inhibition of Skp2, but not RNA interference, modestly decreased Slug protein in PC3 and its docetaxel-resistant subline PC3 DR12. Importantly, chemical inhibition of Skp2 by MLN4924 upregulated p27 and decreased Slug expression in PC3, PC3 DR12, and LAPC4 cells. Novel treatment strategies targeting Skp2 and Slug by the neddylation blockade may be promising in advanced prostate cancer, as recently documented for other aggressive solid tumors.

3 November 2020 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
MGMariam Gachechiladze
Mariam Gachechiladze
JSJozef Skarda
Jozef Skarda
KBKaterina Bouchalova
Katerina Bouchalova
ASAlex Soltermann
Alex Soltermann
Markus JoergerMarkus Joerger
Markus Joerger
Dysfunctional DNA repair with subsequent genome instability and high mutational burden represents a major hallmark of cancer. In established malignant tumors, increased DNA repair capacity mediates resistance to DNA-damaging therapeutics, including cytotoxic drugs, radiotherapy, and selected small molecules including inhibitors of poly (ADP-ribose) polymerase (PARP), Ataxia Telangiectasia Mutated (ATM), ataxia telangiectasia and Rad3-related protein (ATR), and Wee1 kinase (Wee1). In addition, DNA repair deficiency is not only associated with sensitivity to selected anticancer drugs, but also with increased mutagenicity and increased neoantigen load on tumor cells, resulting in increased immunogenicity and improved response to CTLA4- or PD-(L)1 targeting monoclonal antibodies. DNA damage response (DDR) is composed of complex signalling pathways, including the sensing of the DNA damage, signal transduction, cellular response pathways to DNA damage, and activation of DNA repair. DNA double strand breaks (DSBs) are the most dangerous form of DNA damage. Tumor cells are characterised by frequent accumulation of DSBs caused by either endogenous replication stress or the impact of cancer treatment, most prominently chemotherapy and radiotherapy. Therefore, response of cancer cells to DSBs represents a crucial mechanism for how tumors respond to systemic treatment or radiotherapy, and how resistance develops. Ample clinical evidence supports the importance of DDR associated kinases as predictive and prognostic biomarkers in cancer patients. The ATM-CHK2 and ATR-CHK1-WEE1 pathways initiate DNA DSB repair. In the current review, we focus on major DDR associated kinases including ATM, ATR, CHK1, CHK2, and WEE1, and discuss their potential prognostic and predictive value in solid malignancies.

1 March 2019 in Lung Cancer
Verified
Journal Article
Closed access
IÜIvo Überall
Ivo Überall
MGMariam Gachechiladze
Mariam Gachechiladze
Markus JoergerMarkus Joerger
Markus Joerger
JAJosef Anděl
Josef Anděl
PSPetra Smičková
Petra Smičková
JSJozef Skarda
Jozef Skarda

1 January 2014 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
MGMariam Gachechiladze
Mariam Gachechiladze
JSJozef Skarda
Jozef Skarda
MIMaha Ibrahim
Maha Ibrahim
TTTomáš Tichý
Tomáš Tichý
PFPatrik Flodr
Patrik Flodr
ZKZdenek Kolář
Zdenek Kolář
Primary primitive neuroectodermal tumors (PNETs) are extremely rare in the lung and especially in adult women. We describe a case of PNET of the lung with aggressive behavior in 31-year-old woman. Diagnosis was based on histopathological and immunohistochemical studies, and confirmed by molecular genetic analysis of chromosome rearrangements in the EWSR1 gene region. Clinical follow-up, post-mortem findings, and differential diagnosis are also discussed.